title: Plasma PTX3 protein levels inversely correlate with insulin secretion and obesity, whereas visceral adipose tissue PTX3 gene expression is increased in obesity.
abstract: Plasma acutephase protein pentraxin 3 (PTX3) concentration is dysregulated in human obesity and metabolic syndrome. Here, we explore its relationship with insulin secretion and sensitivity, obesity markers, and adipose tissue PTX3 gene expression. Plasma PTX3 protein levels were analyzed in a cohort composed of 27 lean [body mass index (BMI) ≤ 25 kg/m(2)] and 48 overweight (BMI 25-30 kg/m(2)) men (cohort 1). In this cohort, plasma PTX3 was negatively correlated with fasting triglyceride levels and insulin secretion after intravenous and oral glucose administration. Plasma PTX3 protein and PTX3 gene expression in visceral (VAT) and subcutaneous (SAT) whole adipose tissue and adipocyte and stromovascular fractions were analyzed in cohort 2, which was composed of 19 lean, 28 overweight, and 15 obese subjects (BMI >30 kg/m(2)). An inverse association with body weight and waist/hip ratio was observed in cohort 2. In VAT depots, PTX3 mRNA levels were higher in subjects with BMI >25 kg/m(2) than in lean subjects, positively correlated with IL-1β mRNA levels, and higher in the adipocyte than stromovascular fraction. Human preadipocyte SGBS cell line was used to study PTX3 production in response to factors that obesity entails. In SGBS adipocytes, PTX3 gene expression was enhanced by IL-1β and TNFα but not IL-6 or insulin. In conclusion, the negative correlation between PTX3 and glucose-stimulated insulin secretion suggests a role for PTX3 in metabolic control. PTX3 gene expression is upregulated in VAT depots in obesity, despite lower plasma PTX3 protein, and by some proinflammatory cytokines in cultured adipocytes.
authors: Departament de Bioquímica i Biologia Molecular, Universitat de Barcelona, Diagonal, 645, E-08028-Barcelona, Spain. oscarosorioconles@hotmail.com
authors: O
authors: O
authors: Osorio-Conles
authors: M
authors: M
authors: Guitart
authors: M R
authors: MR
authors: Chacón
authors: E
authors: E
authors: Maymo-Masip
authors: J M
authors: JM
authors: Moreno-Navarrete
authors: M
authors: M
authors: Montori-Grau
authors: S
authors: S
authors: Näf
authors: J M
authors: JM
authors: Fernandez-Real
authors: J
authors: J
authors: Vendrell
authors: A M
authors: AM
authors: Gómez-Foix
mesh_terms: D017667:Adipocytes / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D000328:Adult; D000368:Aged; D002097:C-Reactive Protein / Q000032:analysis* / Q000235:genetics* / Q000378:metabolism; D002478:Cells, Cultured; D015331:Cohort Studies; D016207:Cytokines / Q000494:pharmacology; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D007223:Infant; D018836:Inflammation Mediators / Q000494:pharmacology; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D050152:Intra-Abdominal Fat / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood* / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D000683:Serum Amyloid P-Component / Q000032:analysis* / Q000235:genetics* / Q000378:metabolism; D015854:Up-Regulation / Q000187:drug effects; D000099153:Pentraxins
chemical_list: D002097:C-Reactive Protein; D016207:Cytokines; D018836:Inflammation Mediators; D007328:Insulin; D000683:Serum Amyloid P-Component; D000099153:Pentraxins